Simple Custom Led Panel increases Adipogenic Differentiation of Adipose-Derived Mesenchymal Stem Cells through Photobiomodulation.
Ancelia F., Liem IK., Sirait SP.
Laboratory Study, published in J Stem Cells Regen Med (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J Stem Cells Regen Med (2026)
- Country
- India
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42212249
- PMCID
- PMC13214511
- DOI
- 10.46582/jsrm.2201005
Abstract (original English)
Impaired proliferation and differentiation capacity of adipose-derived mesenchymal stem cells (AD-MSCs) in obesity hinder the formation of metabolically healthy adipocytes, thereby aggravating metabolic disorders. Photobiomodulation (PBM) is a simple, non-invasive light-based therapy that primarily uses red and near-infrared light and has been shown to enhance the proliferation and differentiation potential of stem cells, including AD-MSCs. However, the wide variation in PBM parameters used in previous studies necessitates further investigation to determine optimal dosage and delivery methods. This study aimed to construct a simple, easy-to-assemble LED panel for PBM application and to identify an effective dose that stimulates proliferation and adipogenic differentiation of AD-MSCs. The panel delivered 1 J/cm 2 of 660 nm red light, either daily (P1Pro and P1Diff group) or every other day (P2Pro and P2Diff group). No significant differences in total cell count or viability were observed among the groups, indicating that the PBM protocol is safe. KI-67 expression was similar between the P1Pro and control groups (Control: 1.00 ± 0.02; P1Pro: 1.19 ± 0.06, p > 0.05), whereas the P2Pro group showed a significant decrease compared with P1Pro (P2Pro: 0.71 ± 0.06, p = 0.02). The P1Diff group also exhibited a significant increase in expression of adipogenic markers PPARꙋ and CEBPα (1.55
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.